Uveitis Drug Pipeline Analysis Report 2025
Description
The prevalence of uveitis and its associated complications is increasing globally, with the condition occurring in nearly 714 per 100,000 population and accounting for about 25% of all cases of blindness. Further, studies reveal that ongoing inflammation in untreated uveitis and complications linked to this uncontrolled inflammation are likely to be the reason behind 10% of the blindness in the United States. As a result, there is a growing interest in exploring effective treatment options that offer longer-lasting results and prevent vision loss in uveitis patients.
Report Coverage
The Uveitis Drug Pipeline Report by Expert Market Research gives comprehensive insights into uveitis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Uveitis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The uveitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from uveitis.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing uveitis pipeline development activities related to uveitis.
Uveitis Drug Pipeline Outlook
Uveitis refers to an inflammatory disease that involves inflammation of the middle layer of the eye called uvea. The disease can be caused due to infections, idiopathic cases, trauma, and inflammatory diseases. The symptoms can range from redness, pain, and blurry vision to complete vision loss, indicating that prompt treatment is essential to prevent severe complications. Anterior uveitis ranks as the most prevalent type of the condition, comprising nearly 50% of all uveitis cases, whereas posterior uveitis is reported as the least common form.
Uveitis treatment depends on the underlying cause of the disease. Symptom-based treatments typically focus on pain control, inflammation reduction (steroids and nonsteroidal anti-inflammatory drugs (NSAIDs)), and condition-specific treatments. There is an increased emphasis on developing biologic drugs that target specific inflammatory pathways and new classes of small-molecule inhibitors, such as JAK inhibitors, in order to expand treatment options. Further, the rising investment in ophthalmic drug development and advancements in drug delivery technologies are driving the uveitis drug pipeline forward with several highly promising candidates in clinical development.
Uveitis – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of uveitis drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
EMR’s uveitis therapeutic assessment report covers 50+ drug analyses based on drug classes:
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The uveitis report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for uveitis. There are around 109 drugs in phase II for uveitis.
Uveitis – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under uveitis pipeline analysis are corticosteroids, immunosuppressants/immunomodulators, biologic agents, anti-TNF agents, interleukin inhibitors, jak inhibitors, calcineurin inhibitors, anti-VEGF agents, antibiotics and antivirals, and small-molecule inhibitors. The choice of treatment depends on multiple factors including the underlying inflammation and the immune response involved in the condition.
Uveitis Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR uveitis drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in uveitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for uveitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of uveitis drug candidates.
Brepocitinib
Sponsored by Priovant Therapeutics, Inc., brepocitinib is a selective tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor that is being investigated in a Phase 3 clinical trial with around 220 participants having active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
QLETLI
QLETLI (Adalimumab Injection), Bio-Thera's biosimilar to Humira® is undergoing a Phase 4 post-marketing clinical study comprising around 60 participants suffering from uveitis. This prospective study aims to evaluate the clinical efficacy and safety of the drug for non-infectious uveitis.
Izokibep
Uveitis drug candidate Izokibep is in a Phase 2 study to evaluate its clinical activity against treating active non-infectious, intermediate-, posterior- or pan-uveitis that requires high-dose steroids. Developed by clinical biopharma ACELYRIN Inc., Izokibep is a small protein molecule that binds to interleukin-17A with high affinity, thereby acting as its selective, potent inhibitor.
Laquinimod eye drops
Currently, in Phase 1 of a prospective, single-center phase 1 clinical study, Laquinimod eye drops are under investigation for their safety, tolerability, and distribution in 12 human participants for 2 weeks.
Reasons To Buy This Report
The Uveitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for uveitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into uveitis collaborations, regulatory environments, and potential growth opportunities within uveitis pipeline insights.
Key Questions Answered in the Uveitis Pipeline Insight Report
Global Uveitis Drugs Market
Global Clinical Trials Market
Report Coverage
The Uveitis Drug Pipeline Report by Expert Market Research gives comprehensive insights into uveitis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Uveitis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The uveitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from uveitis.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing uveitis pipeline development activities related to uveitis.
Uveitis Drug Pipeline Outlook
Uveitis refers to an inflammatory disease that involves inflammation of the middle layer of the eye called uvea. The disease can be caused due to infections, idiopathic cases, trauma, and inflammatory diseases. The symptoms can range from redness, pain, and blurry vision to complete vision loss, indicating that prompt treatment is essential to prevent severe complications. Anterior uveitis ranks as the most prevalent type of the condition, comprising nearly 50% of all uveitis cases, whereas posterior uveitis is reported as the least common form.
Uveitis treatment depends on the underlying cause of the disease. Symptom-based treatments typically focus on pain control, inflammation reduction (steroids and nonsteroidal anti-inflammatory drugs (NSAIDs)), and condition-specific treatments. There is an increased emphasis on developing biologic drugs that target specific inflammatory pathways and new classes of small-molecule inhibitors, such as JAK inhibitors, in order to expand treatment options. Further, the rising investment in ophthalmic drug development and advancements in drug delivery technologies are driving the uveitis drug pipeline forward with several highly promising candidates in clinical development.
Uveitis – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of uveitis drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s uveitis therapeutic assessment report covers 50+ drug analyses based on drug classes:
- Corticosteroids
- Immunosuppressants/Immunomodulators
- Biologic Agents (Monoclonal Antibodies)
- Anti-TNF Agents
- Interleukin Inhibitors
- JAK Inhibitors
- Calcineurin Inhibitors
- Anti-VEGF Agents
- Antibiotics and Antivirals
- Small-Molecule Inhibitors
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The uveitis report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for uveitis. There are around 109 drugs in phase II for uveitis.
Uveitis – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under uveitis pipeline analysis are corticosteroids, immunosuppressants/immunomodulators, biologic agents, anti-TNF agents, interleukin inhibitors, jak inhibitors, calcineurin inhibitors, anti-VEGF agents, antibiotics and antivirals, and small-molecule inhibitors. The choice of treatment depends on multiple factors including the underlying inflammation and the immune response involved in the condition.
Uveitis Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR uveitis drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in uveitis clinical trials:
- Eli Lilly and Company
- Priovant Therapeutics, Inc.
- Bio-Thera Solutions
- ACELYRIN Inc.
- AbbVie
- Allergan
- Lux Biosciences, Inc.
- Novartis Pharmaceuticals
- Amgen
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for uveitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of uveitis drug candidates.
Brepocitinib
Sponsored by Priovant Therapeutics, Inc., brepocitinib is a selective tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor that is being investigated in a Phase 3 clinical trial with around 220 participants having active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
QLETLI
QLETLI (Adalimumab Injection), Bio-Thera's biosimilar to Humira® is undergoing a Phase 4 post-marketing clinical study comprising around 60 participants suffering from uveitis. This prospective study aims to evaluate the clinical efficacy and safety of the drug for non-infectious uveitis.
Izokibep
Uveitis drug candidate Izokibep is in a Phase 2 study to evaluate its clinical activity against treating active non-infectious, intermediate-, posterior- or pan-uveitis that requires high-dose steroids. Developed by clinical biopharma ACELYRIN Inc., Izokibep is a small protein molecule that binds to interleukin-17A with high affinity, thereby acting as its selective, potent inhibitor.
Laquinimod eye drops
Currently, in Phase 1 of a prospective, single-center phase 1 clinical study, Laquinimod eye drops are under investigation for their safety, tolerability, and distribution in 12 human participants for 2 weeks.
Reasons To Buy This Report
The Uveitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for uveitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into uveitis collaborations, regulatory environments, and potential growth opportunities within uveitis pipeline insights.
Key Questions Answered in the Uveitis Pipeline Insight Report
- Which companies/institutions are leading the uveitis drug development?
- What is the efficacy and safety profile of uveitis pipeline drugs?
- Which company is leading the uveitis pipeline development activities?
- What is the current uveitis commercial assessment?
- What are the opportunities and challenges present in the uveitis drug pipeline landscape?
- What is the efficacy and safety profile of uveitis pipeline drugs?
- Which company is conducting major trials for uveitis drugs?
- Which companies/institutions are involved in uveitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in uveitis?
Global Uveitis Drugs Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Uveitis
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Uveitis
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Uveitis: Epidemiology Snapshot
- 5.1 Uveitis Incidence by Key Markets
- 5.2 Uveitis – Patients Seeking Treatment in Key Markets
- 6 Uveitis: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Uveitis: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Uveitis, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Uveitis Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Uveitis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Brepocitinib PO QD
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 QLETLI
- 10.2.3 Baricitinib
- 10.2.4 Other Drugs
- 11 Uveitis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Izokibep
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 OCS-01
- 11.2.3 Other Drugs
- 12 Uveitis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Laquinimod eye drops
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 RAY121
- 12.2.3 Other Drugs
- 13 Uveitis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Uveitis, Key Drug Pipeline Companies
- 14.1 Eli Lilly and Company
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Priovant Therapeutics, Inc.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Bio-Thera Solutions
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 ACELYRIN Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 AbbVie
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Allergan
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Lux Biosciences, Inc.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Novartis
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Amgen Inc.
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
